Clinical Trial Update: Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating absorption and systemic exposure of AN2690 in patients with onychomycosis (ADME II) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• AN2690

Snippet

Sponsor: Pfizer | Conditions: Onychomycosis | Phase 2 | Status: COMPLETED